Yang Shiqi, Zeng Zhaolin, Yuan Qing, Chen Qian, Wang Zuo, Xie Hui, Liu Jianghua
Department of Metabolism and Endocrinology, Hengyang Medical School, The First Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Department of Clinical Laboratory Medicine, Hengyang Medical School, The First Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Mol Biomed. 2023 Oct 18;4(1):35. doi: 10.1186/s43556-023-00146-y.
Vascular calcification (VC) is highly correlated with cardiovascular disease morbidity and mortality, but anti-VC treatment remains an area to be tackled due to the ill-defined molecular mechanisms. Regardless of the type of VC, it does not depend on a single cell but involves multi-cells/organs to form a complex cellular communication network through the vascular microenvironment to participate in the occurrence and development of VC. Therefore, focusing only on the direct effect of pathological factors on vascular smooth muscle cells (VSMCs) tends to overlook the combined effect of other cells and VSMCs, including VSMCs-VSMCs, ECs-VMSCs, Macrophages-VSMCs, etc. Extracellular vesicles (EVs) are a collective term for tiny vesicles with a membrane structure that are actively secreted by cells, and almost all cells secrete EVs. EVs docked on the surface of receptor cells can directly mediate signal transduction or transfer their contents into the cell to elicit a functional response from the receptor cells. They have been proven to participate in the VC process and have also shown attractive therapeutic prospects. Based on the advantages of EVs and the ability to be detected in body fluids, they may become a novel therapeutic agent, drug delivery vehicle, diagnostic and prognostic biomarker, and potential therapeutic target in the future. This review focuses on the new insight into VC molecular mechanisms from the perspective of crosstalk, summarizes how multi-cells/organs interactions communicate via EVs to regulate VC and the emerging potential of EVs as therapeutic methods in VC. We also summarize preclinical experiments on crosstalk-based and the current state of clinical studies on VC-related measures.
血管钙化(VC)与心血管疾病的发病率和死亡率高度相关,但由于分子机制尚不明确,抗VC治疗仍是一个有待解决的领域。无论VC的类型如何,它都不依赖于单个细胞,而是涉及多个细胞/器官,通过血管微环境形成复杂的细胞通讯网络,参与VC的发生和发展。因此,仅关注病理因素对血管平滑肌细胞(VSMC)的直接作用往往会忽略其他细胞与VSMC的联合作用,包括VSMC-VSMC、内皮细胞(EC)-VSMC、巨噬细胞-VSMC等。细胞外囊泡(EV)是细胞主动分泌的具有膜结构的微小囊泡的统称,几乎所有细胞都会分泌EV。停靠在受体细胞表面的EV可以直接介导信号转导,或将其内容物转移到细胞内,从而引发受体细胞的功能反应。它们已被证明参与VC过程,并且还显示出诱人的治疗前景。基于EV的优势以及在体液中可被检测到的特性,它们未来可能成为一种新型治疗剂、药物递送载体、诊断和预后生物标志物以及潜在的治疗靶点。本综述从细胞间相互作用的角度重点阐述了对VC分子机制的新见解,总结了多细胞/器官如何通过EV相互作用来调节VC,以及EV作为VC治疗方法的新潜力。我们还总结了基于细胞间相互作用的临床前实验以及VC相关措施的临床研究现状。